Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The firm, which started in immunodiagnostics, is constructing a new building to house its molecular biology business.
The approach is based on a new approval of the BacT/ALERT Virtuo system and new indications for the firm's procalcitonin assay.
The firm recently presented data on its first two products that use its proprietary 3Base technology.
The company was founded earlier this year based on an improved method for multiple displacement amplification and a single-cell-variant caller.
The test was approved for lab use, but it runs on a platform with the potential for point-of-care applications.
The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.
The technology has been a core capability of the firm, which is expanding its suite of products to address the broader needs of genomics researchers.
The Bay Area firm is planning to launch a low-cost, microfluidics-based infectious disease diagnostic called the Simple Chip in the next few years.
The method uses graphene-coated silica particles fused to complementary RNA to register impedance changes in the presence of viruses.
The company has also developed software that will enable automated melt curve analysis on Cepheid's existing GeneXpert platforms.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.
